Probiotic YH-15 Curbs Fatty Liver and Weight Gain in Mice by Reshaping Bile Acids

If you have been told your fatty liver or stubborn weight gain might trace back to your gut, a new mouse study offers a concrete biological thread worth following. Researchers found that a probiotic strain called Pediococcus acidilactici YH-15 curbed diet-induced obesity and fatty liver in mice, and traced part of the effect to a bile acid (a fat-digesting compound made by the liver and reshaped by gut bacteria) that appears to switch on a fat-burning signal inside liver cells. The findings, published in the Journal of Functional Foods, do not prove the same pathway works in people, but they give scientists a testable mechanism instead of another vague "probiotics help" headline.

Key takeaways

• A probiotic strain, Pediococcus acidilactici YH-15, reduced weight gain and eased hepatic steatosis (fatty liver) in mice fed a high-fat diet, with stronger effects after long-term dosing than short-term dosing.
• The probiotic reshaped gut bacteria and raised levels of taurocholic acid (TCA), a bile acid that activated a receptor called TGR5 in liver cells and switched on fat-burning proteins.
• The real-world implication: this adds to evidence that specific gut bacteria, not just "probiotics" as a category, can influence bile acid signaling tied to liver fat.
• The headline caveat: everything here comes from mice and cultured liver cells; the proposed bile-acid signaling loop has not been tested in a living animal.

Probiotic YH-15 Curbs Diet-Induced Obesity and Fatty Liver in Mice

Feeding a probiotic called Pediococcus acidilactici YH-15 to obese mice reduced their weight gain and eased hepatic steatosis (fatty liver, the buildup of fat droplets inside liver cells), according to researchers at Beijing University of Agriculture. The team fed male mice a high-fat diet (60% of calories from fat) for 10 weeks to induce obesity, fatty liver, and abnormal blood lipids, then gave a subset of those mice YH-15 by daily oral dosing for either a short or long period. Compared with untreated obese mice, YH-15-treated mice gained less weight, had smaller and less fatty livers on gross and microscopic exam, and showed less fat infiltration in tissue under the skin. Notably, YH-15 had no effect on body weight in mice fed a normal diet, meaning the effect was specific to the obese, high-fat-diet state rather than a generic weight-loss effect.

Why This Matters If You're Managing Fatty Liver or Metabolic Risk

Anyone researching non-alcoholic fatty liver disease (NAFLD), a condition strongly linked to obesity and the gut microbiome, has reason to pay attention to studies like this one. Fatty liver often develops silently alongside weight gain, high cholesterol, and insulin resistance, and current treatment options remain limited, which is why researchers keep probing whether specific gut bacteria can be harnessed as a lever. In this study, YH-15-treated mice also had lower blood levels of liver injury markers (ALT and AST), lower total cholesterol and triglycerides, and a marked drop in LDL cholesterol (the "bad" cholesterol most tied to cardiovascular risk), with the long-term dosing group showing bigger improvements than the short-term group. HDL cholesterol (the "good" cholesterol) barely moved, and fasting blood glucose and fructose were only modestly lower. None of this means a probiotic supplement can currently treat fatty liver in people, but it strengthens the broader case that the gut microbiota-bile acid axis is a legitimate target for future NAFLD research, not just a correlation.

How Researchers Tested the Probiotic in Obese Mice

The study used a multi-layered design meant to connect microbes to mechanism rather than just report an outcome. Male C57BL/6 mice were split into groups: normal chow controls, untreated high-fat-diet controls, and high-fat-diet mice given YH-15 either short-term or long-term (roughly 1 billion colony-forming units per mouse per day by oral dosing). The researchers then combined 16S rRNA gene sequencing (a method for identifying which bacterial species live in the gut), untargeted metabolomics (a scan of small molecules in liver and gut tissue), and transcriptomics (a scan of which genes are turned on or off in the liver). This "multi-omics" approach let them look for coordinated changes across the microbiome, the bile acid pool, and liver gene activity in the same animals, rather than studying each layer in isolation. On the microbiome side, the high-fat diet reduced bacterial diversity and boosted Escherichia-Shigella, a bacterial group often linked to gut inflammation, while YH-15 treatment enriched Lachnospiraceae, a family of bacteria repeatedly associated with gut health and metabolic resilience in prior research.

What This Could Mean If You're Watching Your Own Metabolic Health

For someone already managing weight, cholesterol, or a fatty liver diagnosis, the practical takeaway is not "take this probiotic," since YH-15 has not been tested in humans and is not an approved or verified supplement ingredient at this stage. What is worth discussing with a doctor, if you're already researching gut-liver connections, is the broader and better-established point this study reinforces: the mix of bacteria in your gut can shape circulating bile acids, and bile acids in turn talk to receptors in the liver that control whether it burns or stores fat. The specific bile acid highlighted here, taurocholic acid (TCA), rose in the gut and liver of YH-15-treated mice and tracked closely with the abundance of Lachnospiraceae bacteria, especially after long-term dosing. In a follow-up lab experiment, the researchers added TCA directly to cultured mouse liver cells (AML12 hepatocytes) and found it activated a bile acid receptor called TGR5, increased a fat-burning protein pathway inside the cell nucleus, and boosted two proteins involved in breaking down fat, ATGL and CPT1A. When the researchers blocked TGR5 with an inhibitor drug (SBI-115), those effects were dampened, which supports TGR5 as the likely go-between linking the bile acid to the fat-burning response.

Why the Bile Acid Mechanism Isn't Proven Yet

The authors themselves are explicit that this is an association study, not a proof of cause and effect. They state plainly that although the gut microbiota changes, bile acid changes, and liver gene-activity changes were all "strongly coordinated," the data do not establish that one directly caused another, or that Lachnospiraceae bacteria are what drove the rise in taurocholic acid. The in vitro TGR5 experiment used isolated liver cells in a dish, not a living mouse, and the researchers note that confirming TGR5's role would require blocking or removing the receptor in a live animal, something they have not yet done. They also flag that TCA was identified using an untargeted metabolomics scan without a confirmed chemical standard, so its exact identity and levels still need verification with more targeted lab methods. Combined with the established role of bile acid receptors like TGR5 in fatty liver disease from prior research, the new findings are best read as a plausible mechanism worth testing further, not a settled one.

What Comes Next for YH-15 Research

The logical next steps, which the authors themselves point to, are testing whether blocking TGR5 in a live animal (not just in a dish) erases YH-15's benefits, and running targeted bile acid chemistry to confirm the taurocholic acid finding with certainty. Beyond that, this strain would need to be tested for safety and effect in a human trial before any health claim could be made, a bar that other Pediococcus acidilactici strains investigated for similar high-fat-diet metabolic effects have also not yet cleared. No timeline for human research on YH-15 specifically has been announced.

Common Questions

Is Pediococcus acidilactici YH-15 available as a supplement? The study does not indicate that YH-15 is sold as a commercial probiotic supplement, and no human safety or dosing data exist for it; the results so far are limited to mice and cultured cells.

Does raising taurocholic acid always help the liver? Not necessarily. Bile acids like TCA act through multiple receptors with different effects depending on tissue and context, and this study only tested its effect on one receptor (TGR5) in one cell type; more work is needed to know whether raising TCA is broadly beneficial or context-dependent.

Could this probiotic work the same way in humans? It is possible in principle, since humans also carry TGR5 and produce related bile acids, but mouse gut microbiomes and bile acid pools differ from human ones in composition, so the finding would need to be replicated in human studies before that question can be answered.

References

1. Heyi Zhao, Zixiang Lin, Shangyi Wang, Fuqiang Qiao, Hua Yao (2026). Probiotic YH-15 ameliorates diet-induced obesity and hepatic steatosis associated with bile acid remodeling and TGR5/PPARδ-linked signaling. Journal of Functional Foods. https://doi.org/10.1016/j.jff.2026.107504
2. Yiming Ni, Mengna Lu, Yuan Xu, et al. (2022). The Role of Gut Microbiota-Bile Acids Axis in the Progression of Non-alcoholic Fatty Liver Disease. Frontiers in Microbiology. https://doi.org/10.3389/fmicb.2022.908011
3. Marlena M. Holter, Margot K. Chirikjian, Viraj N. Govani, Bethany P. Cummings (2020). TGR5 Signaling in Hepatic Metabolic Health. Nutrients. https://doi.org/10.3390/nu12092598
4. John Y. L. Chiang, Jessica M. Ferrell (2020). Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy. American Journal of Physiology-Gastrointestinal and Liver Physiology. https://doi.org/10.1152/ajpgi.00223.2019
5. Pediococcus acidilactici FZU106 alleviates high-fat diet-induced lipid metabolism disorder. NIH. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9064835/